BPA or bisphenol A has become well know over the past year as concerns for its effect on human health and well being have been raised. The concerns over BPA in plastics began with baby bottles and spread to include other types of bottles and toys.
BPA or bisphenol A has become well know over the past year as concerns for its effect on human health and well being have been raised. The concerns over BPA in plastics began with baby bottles and spread to include other types of bottles and toys.
BPA is used in the production of two very common polymers: PVC and polycarbonate. As a result of the health concerns over human exposure to BPA, this molecule is now monitored in specific products, including baby bottles and other children's products. Simple and robust test methods are needed to determine the presence and amount of BPA in plastic materials. This application note will present the extraction and HPLC analysis of plastic children's products for BPA.
The study presented here includes extraction of BPA from a toy matrix and analysis with UHPLC. The extraction procedure is intended to simulate the contact routes through which children are likely to encounter BPA. Two different extraction techniques were used to analyze BPA in samples (30 g sample used for each extraction). The first extraction method immersed the sample in 1 L of water, at 40 °C for 24 h (EN 14372). The second immersed the sample with 1 L HCl (0.07 M) at 37 °C for 2 h. Following extraction the samples were analyzed with a PerkinElmer Flexar™ FX-10 UHPLC system including a PerkinElmer Series 200a Fluorescence detector. The separation was performed on a Brownlee Validated C8 Column.
The BPA analyzed with the given LC conditions eluted at 5.43 min. The UHPLC system was calibrated across a range of 1–50 ppb (μg/L) BPA. The limit of quantitation (LOQ) for BPA with the method presented here is 1 ppb. The signal to noise at the LOQ is approximately 10:1. The response across the calibration range fit a linear calibration with an r2 value of 0.9993. Blanks analyzed between standards and samples showed the system was free from any BPA contamination or carryover.
BPA in the extracts of the toy samples were quantified using the calibration curve generated during standard analysis. Figure 1 shows the chromatogram of the water extract of the toy dwarf sample.
Figure 1
The extraction procedure which heated the toy for 24 h in water at 40 °C extracted a significantly higher amount of BPA from the matrix than the extraction in acid. BPA was found in all three water extractions within the calibration range of the standard curve.
As health concerns over exposure to BPA are raised, its analysis in plastics is becoming very important. The PerkinElmer Flexar FX-10 UHPLC system provides a sensitive and robust platform for this analysis. Demonstrated here was a calibration of BPA across a range of 1–50 ppb with a chromatographic run time of less than 10 min. This analysis was applied to three toy samples and BPA was identified in each sample.
PerkinElmer, Inc.
940 Winter Street, Waltham, MA 02451
tel. (800)762-4000; fax (203)944-4904
Website: www.perkinelmer.com.
Mitigating High Sample Volume Consumption in AAV Aggregate Analysis Using a Biozen™ dSEC-7 by SEC-FL
April 15th 2024This application note showcases a Biozen dSEC-7 SEC chemistry/fluorescence detector solution, offering reliable AAV aggregate analysis in under 10 minutes with as little as 0.5 µL of sample. Across four AAV serotypes, resolution between monomer and aggregates remains consistently high, emphasizing Biozen dSEC-7's efficiency and ability to maintain accurate detection at minimal injection volumes. Ideal for routine testing, this solution ensures precise measurement of a CQA with streamlined sample consumption.
Adeno-Associated Virus (AAV) Serotype Screen Using a Biozen™ dSEC-7 Size Exclusion Column
April 15th 2024With its 700 Å large pore silica particle and hydrophilic diol-type surface chemistry, Biozen dSEC-7 provides excellent resolution of monomer from dimer peaks in under 8 minutes across four different AAV serotypes. This capability is crucial for optimizing gene therapy biopharmaceuticals, ensuring thorough analytical scrutiny to select the most appropriate serotype(s) for enhanced therapeutic outcomes and immunogenic profiles.